Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain

After completing a comprehensive review of its research program, Pfizer is rebuilding its late-stage pipeline, with plans to initiate Phase III studies for four new molecular entities and multiple new indications for existing drugs in the next 12 months